IRLAB’s shares are now traded on Nasdaq Stockholm Main Market

September 30, 2020

IRLAB announced today, the commencement of trading in the Company’s shares on Nasdaq Stockholm Main Market. On September 23, 2020, Nasdaq Stockholm’s listing committee approved IRLAB’s application for admission to trading of the Company’s shares of series A on Nasdaq Stockholm Main Market.

[mfn_before_post]

IRLAB announced today, the commencement of trading in the Company's shares on Nasdaq Stockholm Main Market. On September 23, 2020, Nasdaq Stockholm’s listing committee approved IRLAB’s application for admission to trading of the Company’s shares of series A on Nasdaq Stockholm Main Market.

The shares will continue to be traded under the same ticker (IRLAB A) and ISIN code (SE0012675361). No new shares will be issued in connection with the list change and the shareholders in IRLAB do not need to take any measures in connection with the list change. The prospectus prepared by the Company in connection with the listing, was approved and registered by the Swedish Financial Supervisory Authority ("SFSA") on September 25, 2020, and is available on IRLAB's website, www.irlab.se and on SFSA's website, www.fi.se.

“This is an important day for us. Moving to Nasdaq Stockholm's Main Market is an important milestone in our growth journey,” said Nicholas Waters, CEO of IRLAB. “The support from existing shareholders and the welcoming of new shareholders on the main market will enable us in our mission to transform everyday life for patients with Parkinson’s disease.”  

Advisor

MAQS Advokatbyrå is the Company’s legal advisor in connection with the listing on Nasdaq Stockholm.

For more information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.  

[mfn_after_post]

Documents & Links